A conglomerate based in Asia with global interests in real estate development and investment, financial investment, hotels and shipping continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences. One business arm of this conglomerate is a global investment platform focusing on life sciences. Leveraging on the Group’s strong capital base and long term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, the group is starting to build significant presence in US and Greater China.

Within healthcare, the firm looks at cutting-edge biotech therapeutic technologies across small molecule, biologics, and novel therapies. The group focuses on oncology, brain diseases, as well as drug delivery platforms and genomic diagnostics. In terms of development stages, the group focuses on preclinical to early clinical stage assets that are seeking series A/B/C financing.

The firm looks for experienced and competent teams with sector expertise and track record of success. The firm prefers opportunities where they have already identified a healthcare-focused lead investor. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital firm with offices in USA and Asia currently invests from a fund closed in 2017. Its LPs includes major pharmaceutical companies. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. The firm is open to acting as either the lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large corporate’s strategic venture arm is focused on venture and growth stage investments in several verticals including healthcare, IT and energy. The group will make investments from $5M-$30M and is very flexible with structure and size, with approximately 80% of investments in the form of equity and the other 20% in debt. The group will both lead or co-invest and typically seeks board representation although it is not a requirement. The group is focused on companies in the United States, but may look at some international opportunities in select geographies.

The firm is interested in medical devices, healthcare services, digital health, and biopharma and the group is looking for de-risked opportunities in these areas. In the medical device space, the group is interested in devices that have achieved FDA approval and have reimbursement established. Digital health/healthcare IT companies should have commercial traction and a minimum of 10-20 paying customers. The group is looking for healthcare services companies that have proven their business model and are in need of growth capital. In the biopharma space, the group avoids opportunities with binary scientific, development, or clinical risk and is interested in areas such as specialty pharma, outsourced services, platform technologies, etc.

The firm places a large emphasis on high quality management teams and will work with companies with an incomplete management team as long as the key members of management are in place and have significant experience/expertise in the area they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm is a venture capital firm that invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the East Coast has assets under management of about $135M and is investing from its third fund of outside capital, which closed in 2012. The firm invests in technology-enhanced services, and about 80% of the firm’s investments are in digital health technologies. Investments are in the form of equity or (less frequently) convertible debt, and the firm typically invests $500,000-$1.5 M. The firm invests in about 3-4 companies per year, and investments are typically made in Series A rounds. The firm primarily invests in the Northeast and Mid-Atlantic, but will consider investments outside those regions.

The firm invests broadly in the healthcare IT and analytics space, with past investments including a diagnostic platform, consumer wellness apps and health-focused media. They look for companies which provide software and data services to providers, payers, biopharmaceutical firms, and patients. The firm will consider investments related to any indication, but does not consider medical devices or therapeutic drugs. The firm invest only in companies that have fully developed a product.

The firm prefers to invest in companies that have existing revenues, but may consider pre-revenue companies with other strong evidence of their product’s market momentum such as adoption by free users. They like to see recurring revenue, high gross margins, and well-understood customer economics. The firm invests only in privately held companies, but has no other set requirements for management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California firm invests globally across industries from two active funds, one that is investing primarily in Series A and B rounds, and the other fund is investing in growth stage opportunities. The firm is usually an active lead investor, but may also invest as part of broader syndicates. Typical Series A investments are $5-10M up front with additional capital reserved. The firm supports portfolio companies through entrepreneurial experience, network, and recruiting.

The firm has a strategic focus in life sciences and digital health. Special interest areas include therapeutics (especially platform technologies), digital health (especially products that improve health outcomes), and novel applications of transformative technologies (such as genomics and synthetic biology).

The firm believes passionately that their role is to support and serve great management teams and entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based family office invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.